News & Updates

Show Multimedia Only

Tofacitinib safe, effective in UC, but response fades after dose reduction

06 Jun 2023 by

Treatment with tofacitinib is both safe and effective in a real-world setting, as shown in a Canada study, in which a third of patients with ulcerative colitis (UC) achieved clinical remission with few serious adverse events. However, nearly half of them have lost response following dose de-escalation, and this is only partially recaptured with re-escalation.

Tofacitinib safe, effective in UC, but response fades after dose reduction

06 Jun 2023

Genetically predicted depression linked to multiple gastrointestinal disorders

31 May 2023

Genetic predisposition to major depressive disorder has the potential to increase the risk of gastrointestinal disorders such as gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), peptic ulcer disease, and nonalcoholic fatty liver disease (NAFLD), according to the results of a Mendelian randomization study.

Genetically predicted depression linked to multiple gastrointestinal disorders

31 May 2023

Cancer incidence uncommon among low-risk pancreatic cysts during extended surveillance

31 May 2023

Low-risk branch duct intraductal papillary mucinous neoplasms (BD-IPMNs) appear to have a positive outlook, with the results of a recent meta-analysis showing that the incidence of advanced neoplasia during extended surveillance is low.

Cancer incidence uncommon among low-risk pancreatic cysts during extended surveillance

31 May 2023

Subgroup analysis CONFIRMs telipressin potential for treating HRS, alcoholic hepatitis

30 May 2023 by

In individuals with hepatorenal syndrome (HRS) compounded by alcoholic hepatitis (AH), treatment with the synthetic, long-acting vasopressin analogue terlipressin led to the achievement of verified HRS reversal, a subgroup analysis of the phase III CONFIRM trial has shown.

Subgroup analysis CONFIRMs telipressin potential for treating HRS, alcoholic hepatitis

30 May 2023

New data fortify obeticholic acid role in NASH treatment

29 May 2023 by

In the new analysis of the REGENERATE trial, the FXR* agonist obeticholic acid (OCA) was generally well tolerated and demonstrated a favourable safety profile in patients with nonalcoholic steatohepatitis (NASH).

New data fortify obeticholic acid role in NASH treatment

29 May 2023

Sofosbuvir/velpatasvir effective, safe for paediatric HCV

25 May 2023 by

The direct-acting antiviral (DAA) sofosbuvir/velpatasvir (SOF/VEL) was effective and safe for the treatment of chronic hepatitis C virus (HCV) infection in individuals aged 6–18 years, the PANDAA-PED study has shown.

Sofosbuvir/velpatasvir effective, safe for paediatric HCV

25 May 2023

Vedolizumab prevents postop CD recurrence: new indication likely

24 May 2023 by

Patients with resected Crohn’s disease (CD) who were treated with the gut-selective α4β7-integrin inhibitor vedolizumab were less likely to have endoscopic signs of recurrence compared with placebo in the Reprevio study presented at DDW 2023.

Vedolizumab prevents postop CD recurrence: new indication likely

24 May 2023

Fexuprazan brings relief in erosive esophagitis, noninferior to esomeprazole

23 May 2023 by

The novel potassium-competitive acid blocker fexuprazan shows comparable safety and efficacy to the proton pump inhibitor esomeprazole in the treatment of Chinese patients with erosive esophagitis, as shown in the results of a phase III study presented at DDW 2023.

Fexuprazan brings relief in erosive esophagitis, noninferior to esomeprazole

23 May 2023

LIBERTY-UC: Maintenance subcutaneous infliximab eases moderate-to-severe UC

22 May 2023 by

The subcutaneous infliximab formulation CT-P13 appears beneficial in the maintenance treatment of patients with moderately to severely active ulcerative colitis (UC), with data from the phase III study LIBERTY-UC showing that the drug outperforms placebo in multiple endpoints.

LIBERTY-UC: Maintenance subcutaneous infliximab eases moderate-to-severe UC

22 May 2023

Is long-term ustekinumab safe and effective in children with Crohn’s disease?

22 May 2023 by

Use of ustekinumab for up to 4 years in paediatric patients with Crohn’s disease (CD) shows similar efficacy, safety, pharmacokinetics (PK), and immunogenicity to that seen in adult patients, according to the results of the UniStar study long-term extension.

Is long-term ustekinumab safe and effective in children with Crohn’s disease?

22 May 2023

News & Updates

Showing Gastroenterology articles

Showing

Specialty:

Tofacitinib safe, effective in UC, but response fades after dose reduction

Tofacitinib safe, effective in UC, but response fades after dose reduction

Genetically predicted depression linked to multiple gastrointestinal disorders

Genetically predicted depression linked to multiple gastrointestinal disorders

Cancer incidence uncommon among low-risk pancreatic cysts during extended surveillance

Cancer incidence uncommon among low-risk pancreatic cysts during extended surveillance

Subgroup analysis CONFIRMs telipressin potential for treating HRS, alcoholic hepatitis

Subgroup analysis CONFIRMs telipressin potential for treating HRS, alcoholic hepatitis

New data fortify obeticholic acid role in NASH treatment

New data fortify obeticholic acid role in NASH treatment

Sofosbuvir/velpatasvir effective, safe for paediatric HCV

Sofosbuvir/velpatasvir effective, safe for paediatric HCV

Vedolizumab prevents postop CD recurrence: new indication likely

Vedolizumab prevents postop CD recurrence: new indication likely

Fexuprazan brings relief in erosive esophagitis, noninferior to esomeprazole

Fexuprazan brings relief in erosive esophagitis, noninferior to esomeprazole

LIBERTY-UC: Maintenance subcutaneous infliximab eases moderate-to-severe UC

LIBERTY-UC: Maintenance subcutaneous infliximab eases moderate-to-severe UC

Is long-term ustekinumab safe and effective in children with Crohn’s disease?

Is long-term ustekinumab safe and effective in children with Crohn’s disease?